Cargando…

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma

BACKGROUND: Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our previous data with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartaglione, Sara, Mancini, Patrizia, Viggiani, Valentina, Chirletti, Piero, Angeloni, Antonio, Anastasi, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136623/
https://www.ncbi.nlm.nih.gov/pubmed/34015010
http://dx.doi.org/10.1371/journal.pone.0251656
_version_ 1783695462691241984
author Tartaglione, Sara
Mancini, Patrizia
Viggiani, Valentina
Chirletti, Piero
Angeloni, Antonio
Anastasi, Emanuela
author_facet Tartaglione, Sara
Mancini, Patrizia
Viggiani, Valentina
Chirletti, Piero
Angeloni, Antonio
Anastasi, Emanuela
author_sort Tartaglione, Sara
collection PubMed
description BACKGROUND: Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our previous data with a larger sample size and to assess a possible role of PIVKA-II in predicting surgical success. Additionally, to further evaluate the hypothesis of a direct PIVKA-II production by PDAC cells, we examined PIVKA-II tissue expression in a case of PDAC using immunofluorescence. METHODS: We enrolled 76 newly diagnosed PDAC patients and selected 11 patients to determine PIVKA-II levels also after surgical resection. An immunofluorescence (IF) study of PIVKA-II tissue expression was carried out in one of them. PIVKA-II serum values were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Belgium). RESULTS: PIVKA-II serum levels were above the cut-off at baseline in 71 patients (94%) with a median value of 464 mAU/Ml (range 27–40783 mAU/mL); the sensitivity and specificity were 78.67% and 90.67% respectively. Patients with pre-operative PIVKA-II positivity showed a significant decrease (P < 0.015) of median PIVKA-II serum concentrations after surgery: 820 (91–40783) mAU/mL at diagnosis vs 123 (31–4666) mAU/mL post-operatively. IF assay on PDAC sections demonstrated PIVKA-II expression in cancer cells. CONCLUSION: These data are the first showing a decreased PIVKA-II serum levels after surgery in PDAC patients and reporting PIVKA-II expression in PDAC tissue. Further studies are needed to confirm these findings and to determine PIVKA-II usefulness in diagnosing and monitoring PDAC patients.
format Online
Article
Text
id pubmed-8136623
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-81366232021-05-27 PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma Tartaglione, Sara Mancini, Patrizia Viggiani, Valentina Chirletti, Piero Angeloni, Antonio Anastasi, Emanuela PLoS One Research Article BACKGROUND: Pancreatic adenocarcinoma (PDAC) is an incurable cancer without adequate tumor markers. Our previous study has showed a better diagnostic performance of Protein Induced by Vitamin K Absence II (PIVKA-II) compared to currently used PDAC biomarkers. To corroborate our previous data with a larger sample size and to assess a possible role of PIVKA-II in predicting surgical success. Additionally, to further evaluate the hypothesis of a direct PIVKA-II production by PDAC cells, we examined PIVKA-II tissue expression in a case of PDAC using immunofluorescence. METHODS: We enrolled 76 newly diagnosed PDAC patients and selected 11 patients to determine PIVKA-II levels also after surgical resection. An immunofluorescence (IF) study of PIVKA-II tissue expression was carried out in one of them. PIVKA-II serum values were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Belgium). RESULTS: PIVKA-II serum levels were above the cut-off at baseline in 71 patients (94%) with a median value of 464 mAU/Ml (range 27–40783 mAU/mL); the sensitivity and specificity were 78.67% and 90.67% respectively. Patients with pre-operative PIVKA-II positivity showed a significant decrease (P < 0.015) of median PIVKA-II serum concentrations after surgery: 820 (91–40783) mAU/mL at diagnosis vs 123 (31–4666) mAU/mL post-operatively. IF assay on PDAC sections demonstrated PIVKA-II expression in cancer cells. CONCLUSION: These data are the first showing a decreased PIVKA-II serum levels after surgery in PDAC patients and reporting PIVKA-II expression in PDAC tissue. Further studies are needed to confirm these findings and to determine PIVKA-II usefulness in diagnosing and monitoring PDAC patients. Public Library of Science 2021-05-20 /pmc/articles/PMC8136623/ /pubmed/34015010 http://dx.doi.org/10.1371/journal.pone.0251656 Text en © 2021 Tartaglione et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tartaglione, Sara
Mancini, Patrizia
Viggiani, Valentina
Chirletti, Piero
Angeloni, Antonio
Anastasi, Emanuela
PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
title PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
title_full PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
title_fullStr PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
title_full_unstemmed PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
title_short PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
title_sort pivka-ii: a biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136623/
https://www.ncbi.nlm.nih.gov/pubmed/34015010
http://dx.doi.org/10.1371/journal.pone.0251656
work_keys_str_mv AT tartaglionesara pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma
AT mancinipatrizia pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma
AT viggianivalentina pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma
AT chirlettipiero pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma
AT angeloniantonio pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma
AT anastasiemanuela pivkaiiabiomarkerfordiagnosingandmonitoringpatientswithpancreaticadenocarcinoma